{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/65c527ff1d03750017dc1eaf?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett","description":"<p><strong>Episode 8 (February 9th, 2024): </strong>Intellia and Ultragenyx gave updates on their clinical trials for gene therapies for inherited rare diseases. Novo Holdings, which manages the assets of the foundation that controls Novo Nordisk, agreed to buy Catalent for $16.5 billion to keep up with the high demand for its hit drugs Wegovy and Ozempic. Spatial biology tools developer NanoString Technologies filed for bankruptcy, blaming the $31 million jury award assessed against it last November in a patent infringement case filed by rival 10x Genomics. Plus, an interview with Simon Barnett, research director at Dimension.</p><p>&nbsp;</p><p>Listed below are key references to the <em>GEN</em> stories, media, and other items discussed in this episode of <em>Touching Base</em>:</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/news/gene-therapy-for-hereditary-angioedema-shows-success-in-patients/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Gene Therapy for Hereditary Angioedema Shows Success in Patients</strong></a><strong> </strong></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>GEN</em>, February 5, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/gen-edge/ultragenyxs-gene-therapy-ameliorates-pediatric-neurodegenerative-disorder/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Ultragenyx’s Gene Therapy Ameliorates Pediatric Neurodegenerative Disorder&nbsp;</strong></a></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By Jonathan Grinstein, <em>GEN Edge</em>, February 7, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/genome-editing/crispr-repaired-t-cells-may-treat-fatal-inflammatory-diseases/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>CRISPR-Repaired T Cells May Treat Fatal Inflammatory Diseases&nbsp;</strong></a></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>GEN</em>, February 5, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/news/nanostring-files-for-chapter-11-bankruptcy-launches-strategic-review/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>NanoString Files for Chapter 11 Bankruptcy, Launches Strategic Review&nbsp;</strong></a></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By Alex Philippidis, <em>GEN</em>, February 5, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/novo-holdings-buys-catalent-for-16-5b-sells-three-sites-to-novo-nordisk-for-11b/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Novo Holdings Buys Catalent for $16.5B; Sells Three Sites to Novo Nordisk for $11B&nbsp;</strong></a></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By Alex Philippidis, <em>GEN</em>, February 5, 2024</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}